167 related articles for article (PubMed ID: 34642938)
1. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
[No Abstract] [Full Text] [Related]
2. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
[TBL] [Abstract][Full Text] [Related]
4. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Wilson WH; Wright GW; Huang DW; Hodkinson B; Balasubramanian S; Fan Y; Vermeulen J; Shreeve M; Staudt LM
Cancer Cell; 2021 Dec; 39(12):1643-1653.e3. PubMed ID: 34739844
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Oberic L; Peyrade F; Puyade M; Bonnet C; Dartigues-Cuillères P; Fabiani B; Ruminy P; Maisonneuve H; Abraham J; Thieblemont C; Feugier P; Salles G; Bijou F; Pica GM; Damaj G; Haioun C; Casasnovas RO; Farhat H; Le Calloch R; Waultier-Rascalou A; Malak S; Paget J; Gat E; Tilly H; Jardin F
J Clin Oncol; 2021 Apr; 39(11):1203-1213. PubMed ID: 33444079
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Di Raimondo C; Abdulla FR; Zain J; Querfeld C; Rosen ST
Br J Haematol; 2019 Nov; 187(3):e79-e82. PubMed ID: 31566707
[No Abstract] [Full Text] [Related]
7. Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.
Dührsen U; Tometten M; Kroschinsky F; Ganser A; Ibach S; Bertram S; Hüttmann A
Blood Cancer J; 2021 May; 11(5):95. PubMed ID: 34001867
[No Abstract] [Full Text] [Related]
8. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
Houillier C; Chabrot CM; Moles-Moreau MP; Willems L; Ahle G; Waultier-Rascalou A; Fornecker LM; Hoang-Xuan K; Soussain C
Neurology; 2021 Sep; 97(13):628-631. PubMed ID: 34580183
[TBL] [Abstract][Full Text] [Related]
10. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH; Nastoupil L; De Vos S; Knapp M; Flinn IW; Chen R; Advani RH; Bhatia S; Martin P; Mena R; Davis RE; Neelapu SS; Eckert K; Ping J; Co M; Beaupre DM; Neuenburg JK; Palomba ML
Br J Haematol; 2020 May; 189(4):650-660. PubMed ID: 32180219
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report.
Li C; Zhang X; Zhu D; Bu X; Wang L; Zhao P
Ann Hematol; 2023 Dec; 102(12):3625-3627. PubMed ID: 37608197
[No Abstract] [Full Text] [Related]
12. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Xu PP; Shi ZY; Qian Y; Cheng S; Zhu Y; Jiang L; Li JF; Fang H; Huang HY; Yi HM; Ouyang BS; Wang L; Zhao WL
Lancet Healthy Longev; 2022 Jul; 3(7):e481-e490. PubMed ID: 36102758
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
15. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
16. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Zinzani PL; Pellegrini C; Argnani L; Broccoli A
Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
[No Abstract] [Full Text] [Related]
17. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
18. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.
Zoli S; Pellegrini C; Casadei B; Broccoli A; Argnani L; Nanni L; Stefoni V; Zinzani PL
Chemotherapy; 2024; 69(1):23-26. PubMed ID: 37913761
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
[TBL] [Abstract][Full Text] [Related]
20. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
